Why undergoing this examination?

In recent years, knowledge of breast cancer has evolved significantly and this condition is currently considered a complex and heterogeneous pathology. Therefore, distinct factors should be considered to determine the patient’s prognosis. Women with breast cancer with early phaseestrogen receptor expression, usually have a good prognosis. However, in this population, about 50% of recurrences occur after five years of diagnosis. An imminent need in the management of breast cancer with estrogen receptor expression is to identify women at increased risk of late recurrence.

What is this exam?

Prosigna (PAM50) was developed from a PAM50 gene signature that provides the patient’s Risk-Of-Recurrence (ROR) information based on three factors such as tumor size, intrinsic molecular subtype and tumor proliferation status.

For whom is it indicated?

Postmenopausal women who have been mastectomized as a result of breast cancer and who have the following characteristics:
• Positive hormone receptors, negative ganglia, stage I and II breast cancer.
• Positive hormone receptors, ganglia positive (1 – 3.4 or more positive ganglia), stage II or IIIA breast cancer.


nCounter Dx Analysis System


• Guaranteed from the experience of the Synlab group, the absolute European leader in laboratory diagnosis.
• Validated in two clinical studies that evaluated more than 2,400 postmenopausal women with early-stage breast cancer.
• Approved by the United States (FDA) and European (EMA) regulatory agencies as a prognostic tool in early breast cancer.
• It provides assessment of the risk of recurrence over up to 10 years and the intrinsic subtype.

Extra information

DOCUMENTATION – Available on Extranet for clients:
• Informed Consent.
• Clinical Questionnaire.
• Fasting is not necessary for the test.

Delivery Time
10 working days
Type of Sample
Tumor fragment in paraffin tissue block (see sample preparation instructions)

Subscribe to our newsletter\n

Subscribe to receive news about our exams